Trends in Cardiovascular Mortality Among Patients With Alzheimer's Disease in the United States from 1999 to 2020.

Alzheimer's disease cardiovascular-mortality

Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
20 Nov 2023
Historique:
received: 09 10 2023
revised: 24 10 2023
accepted: 14 11 2023
pubmed: 23 11 2023
medline: 23 11 2023
entrez: 22 11 2023
Statut: aheadofprint

Résumé

This study aimed to compare the trends in cardiovascular diseases (CVDs)-related mortality in patients with Alzheimer's disease (AD) and in the general population aged ≥65 years. Data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research Multiple Cause of Death dataset were used to determine national trends in age-adjusted CVD mortality rates (AAMR) and average annual percent change (AAPC) values in patients with AD and the overall population aged ≥65 years from 1999 to 2020. Data for AAMR and AAPCs were also stratified by age, gender, ethnicity/race, geographical region, urbanization status, and subgroups of CVD. Trends in the overall AAMR stratified by gender, age, ethnicity/race, geographical region, urbanization status, and CVD subgroups were statistically different between patients with AD and the overall population (overall AAPC for CVD mortality rate in patients with AD = -3.5% [confidence interval -4.1% to -2.9%] vs -2.6% [confidence interval -2.3% to -2.9%] in overall population, p = 0.01). Differences in the decrease in the mortality rates between patients with AD and the overall population were found to be statistically different across all stratifications except for the change in the mortality rates for hypertensive diseases (p = 0.05), females (p = 0.2), and Asian or Pacific Islanders (p = 0.09). In conclusion, CVD-related mortality in patients with AD decreased over the last 2 decades, and decreases were more prominent than seen in the general population aged ≥65 years. These results may help focus public health efforts to optimize CVD health in patients with AD.

Identifiants

pubmed: 37993040
pii: S0002-9149(23)01340-1
doi: 10.1016/j.amjcard.2023.11.044
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no competing interests to declare.

Auteurs

Sruthi Ranganathan (S)

School of Medicine, Cambridge University, Cambridge, United Kingdom.

Dmitry Abramov (D)

Division of Cardiology, Department of Medicine, Loma Linda University Medical Center, Loma Linda, California.

Nicholas W S Chew (NWS)

Department of Cardiology, National University Heart Centre, National University Health System, Singapore, Singapore.

Christian Mallen (C)

School of Medicine, Keele University, Staffordshire, United Kingdom.

Michelle Marshall (M)

Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel.

Ofer Kobo (O)

School of Medicine, Keele University, Staffordshire, United Kingdom; Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel.

Mamas A Mamas (MA)

Keele Cardiovascular Research Group, Keele University, Keele, United Kingdom. Electronic address: mamasmamas1@yahoo.co.uk.

Classifications MeSH